Stimulation med 0,3 mg rekombinant human thyrotropin øger effekten af 131 I-behandling hos patienter med atoksisk nodulær struma: En prospektiv, randomiseret, dobbeltblindet undersøgelse - sekundærpublikation

Viveque Egsgaard Nielsen; Steen Joop Bonnema; Henrik Boel Jørgensen; Peter Grupe; Laszlo Hegedüs

Stimulation med 0,3 mg rekombinant human thyrotropin øger effekten af 131 I-behandling hos patienter med atoksisk nodulær struma: En prospektiv, randomiseret, dobbeltblindet undersøgelse - sekundærpublikation

Translated title of the contribution: Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication

Viveque Egsgaard Nielsen, Steen Joop Bonnema, Henrik Boel Jørgensen, Peter Grupe, Laszlo Hegedüs

KI, OUH, Research unit of Endocrinology (Odense)

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH.
Udgivelsesdato: 2006-Nov-20

Translated title of the contribution	Stimulation with 0,3 mg recombinant human thyrotropin (rhTSH) increases the effect of 131I therapy in patients with nontoxic nodular goiter. A prospective, randomized, double-blind trial--secondary publication
Original language	Danish
Journal	Ugeskrift for Læger
Volume	168
Issue number	47
Pages (from-to)	4098-4101
ISSN	0041-5782
Publication status	Published - 20. Nov 2006

Cite this

@article{f3b98c60aacf11dfb62d000ea68e967b,

title = "Stimulation med 0,3 mg rekombinant human thyrotropin {\o}ger effekten af 131 I-behandling hos patienter med atoksisk nodul{\ae}r struma: En prospektiv, randomiseret, dobbeltblindet unders{\o}gelse - sekund{\ae}rpublikation",

abstract = "In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH. Udgivelsesdato: 2006-Nov-20",

author = "Nielsen, {Viveque Egsgaard} and Bonnema, {Steen Joop} and J{\o}rgensen, {Henrik Boel} and Peter Grupe and Laszlo Heged{\"u}s",

year = "2006",

month = nov,

day = "20",

language = "Dansk",

volume = "168",

pages = "4098--4101",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

Stimulation med 0,3 mg rekombinant human thyrotropin øger effekten af 131 I-behandling hos patienter med atoksisk nodulær struma: En prospektiv, randomiseret, dobbeltblindet undersøgelse - sekundærpublikation. / Nielsen, Viveque Egsgaard ; Bonnema, Steen Joop; Jørgensen, Henrik Boel et al.
In: Ugeskrift for Læger, Vol. 168, No. 47, 20.11.2006, p. 4098-4101.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Stimulation med 0,3 mg rekombinant human thyrotropin øger effekten af 131 I-behandling hos patienter med atoksisk nodulær struma

T2 - En prospektiv, randomiseret, dobbeltblindet undersøgelse - sekundærpublikation

AU - Nielsen, Viveque Egsgaard

AU - Bonnema, Steen Joop

AU - Jørgensen, Henrik Boel

AU - Grupe, Peter

AU - Hegedüs, Laszlo

PY - 2006/11/20

Y1 - 2006/11/20

N2 - In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH. Udgivelsesdato: 2006-Nov-20

AB - In a randomized, double-blind, placebo-controlled trial, 57 patients with nontoxic nodular goiter were stimulated with either 0.3 mg recombinant human thyrotropin (rhTSH) or placebo before radioactive iodine 131I therapy. After one year the goiter reduction had improved by 35% compared to conventional 131I therapy. The difference was most pronounced in patients with a large goiter. Adverse effects, including development of permanent hypothyroidism, were significantly more frequent in the rhTSH group. Patient satisfaction was high and uninfluenced by the use of rhTSH. Udgivelsesdato: 2006-Nov-20

M3 - Tidsskriftartikel

C2 - 17134608

SN - 0041-5782

VL - 168

SP - 4098

EP - 4101

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 47

ER -